Research Article
Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
Table 1
Cytotoxic activity of IL-4Rα-lytic hybrid peptide against BTC.
| | Cell line | IC50 (μM) | IC50 ratio | | Lytic peptide alone | IL-4Rα-lytic peptide | (Lytic/IL-4Rα-lytic ) |
| | TGBC-1-TKB | 16.99 ± 1.28 | 2.17 ± 0.54 | 7.83 | | TGBC-44-TKB | 21.37 ± 4.91 | 3.27 ± 0.51 | 6.53 | | CCKS-1 | 15.83 ± 0.02 | 2.73 ± 1.26 | 5.80 | | KKU-100 | 18.93 ± 3.85 | 2.99 ± 1.01 | 6.34 | | KMBC | 18.50 ± 1.65 | 3.25 ± 1.36 | 5.69 | | SK-1 | 13.44 ± 0.42 | 4.47 ± 0.40 | 3.00 |
|
|
IC50 values (peptide concentration inducing 50% inhibition of control cell growth) are represented as mean ± SD from triplicate determinations.
|
